BRIEF-Qyuns Therapeutics Enters License & Collaboration Agreement With LE2025 Therapeutics AG

Reuters2025-12-22

BRIEF-Qyuns <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Enters License & Collaboration Agreement With LE2025 Therapeutics AG

Dec 22 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK:

ENTERS LICENSE & COLLABORATION AGREEMENT WITH LE2025 THERAPEUTICS AG
GROUP TO RECEIVE TOTAL OF UP TO $700 MILLION PAYMENTS, INCLUDING UPFRONT PAYMENT, OTHERS
LE2025 GRANTED EXCLUSIVE RIGHTS FOR QX027N DEVELOPMENT GLOBALLY EXCEPT FROM MAINLAND CHINA, OTHERS

Further company coverage: 2509.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593859174?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 09:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593859174","market":"fut","top_or_hot":-1,"title":"BRIEF-Qyuns Therapeutics Enters License & Collaboration Agreement With LE2025 Therapeutics AG","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Enters License &amp; Collaboration Agreement With LE2025 Therapeutics AG</title></head><body><p><span>Dec 22 (Reuters)</span><span> - </span>Qyuns Therapeutics Co Ltd <span>2509.HK</span>:</p><ul><li><p>ENTERS LICENSE &amp; COLLABORATION AGREEMENT WITH LE2025 THERAPEUTICS AG</p></li><li><p>GROUP TO RECEIVE TOTAL OF UP TO $700 MILLION PAYMENTS, INCLUDING UPFRONT PAYMENT, OTHERS</p></li><li><p>LE2025 GRANTED EXCLUSIVE RIGHTS FOR QX027N DEVELOPMENT GLOBALLY EXCEPT FROM MAINLAND CHINA, OTHERS</p></li></ul><p>Further company coverage: <span>2509.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Qyuns Therapeutics Enters License & Collaboration Agreement With LE2025 Therapeutics AG</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Qyuns Therapeutics Enters License & Collaboration Agreement With LE2025 Therapeutics AG\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-22 09:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Enters License &amp; Collaboration Agreement With LE2025 Therapeutics AG</title></head><body><p><span>Dec 22 (Reuters)</span><span> - </span>Qyuns Therapeutics Co Ltd <span>2509.HK</span>:</p><ul><li><p>ENTERS LICENSE &amp; COLLABORATION AGREEMENT WITH LE2025 THERAPEUTICS AG</p></li><li><p>GROUP TO RECEIVE TOTAL OF UP TO $700 MILLION PAYMENTS, INCLUDING UPFRONT PAYMENT, OTHERS</p></li><li><p>LE2025 GRANTED EXCLUSIVE RIGHTS FOR QX027N DEVELOPMENT GLOBALLY EXCEPT FROM MAINLAND CHINA, OTHERS</p></li></ul><p>Further company coverage: <span>2509.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XQ00Q:1","article_id":"2593859174","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593859174","pubTimestamp":1766365723,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Qyuns Therapeutics Enters License & Collaboration Agreement With LE2025 Therapeutics AGDec 22  - Qyuns Therapeutics Co Ltd 2509.HK:ENTERS LICENSE & COLLABORATION AGREEMENT WITH LE2025 THERAPEUTICS AGGROUP TO RECEIVE TOTAL OF UP TO $700 MILLION PAYMENTS, INCLUDING UPFRONT PAYMENT, OTHERSLE2025 GRANTED EXCLUSIVE RIGHTS FOR QX027N DEVELOPMENT GLOBALLY EXCEPT FROM MAINLAND CHINA, OTHERSFurther company coverage: 2509.HK ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B","BK1161":"生物科技"},"translate_title":"简介-Qyuns Therapeutics与LE2025 Therapeutics AG签订许可和合作协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":0.9},"content_text":"BRIEF-Qyuns Therapeutics Enters License & Collaboration Agreement With LE2025 Therapeutics AGDec 22 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK:ENTERS LICENSE & COLLABORATION AGREEMENT WITH LE2025 THERAPEUTICS AGGROUP TO RECEIVE TOTAL OF UP TO $700 MILLION PAYMENTS, INCLUDING UPFRONT PAYMENT, OTHERSLE2025 GRANTED EXCLUSIVE RIGHTS FOR QX027N DEVELOPMENT GLOBALLY EXCEPT FROM MAINLAND CHINA, OTHERSFurther company coverage: 2509.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593859174","isCrawlerRequest":true}